Published in Haematologica on January 15, 2010
Genetics of familial forms of thrombocytopenia. Hum Genet (2012) 1.24
Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost (2013) 1.08
Demonstration of novel gain-of-function mutations of αIIbβ3: association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med (2013) 0.87
Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer. Breast Cancer Res (2011) 0.82
αIIbβ3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. Proc Natl Acad Sci U S A (2015) 0.79
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica (2015) 0.78
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One (2014) 0.78
Regulation of platelet beta 3 integrins. Haematologica (2010) 0.75
Structural and thermodynamic basis of proline-induced transmembrane complex stabilization. Sci Rep (2016) 0.75
Integrins: bidirectional, allosteric signaling machines. Cell (2002) 36.25
Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem (2000) 9.96
Talin binding to integrin beta tails: a final common step in integrin activation. Science (2003) 7.56
Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct (2004) 7.52
Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem (1996) 4.45
Sphingolipid organization in biomembranes: what physical studies of model membranes reveal. J Cell Sci (1998) 3.25
Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science (2003) 3.22
Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood (2004) 3.05
Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood (1990) 3.02
Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension (2005) 2.62
Crosslinking a lipid raft component triggers liquid ordered-liquid disordered phase separation in model plasma membranes. Proc Natl Acad Sci U S A (2005) 2.60
Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails. J Cell Biol (1999) 2.55
Cholesterol depletion induces large scale domain segregation in living cell membranes. Proc Natl Acad Sci U S A (2001) 2.41
The challenge of lipid rafts. J Lipid Res (2008) 2.23
Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin alphaIIb beta3. J Cell Biol (1998) 2.11
Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol (1993) 2.08
Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A (1992) 1.95
Transmembrane domain helix packing stabilizes integrin alphaIIbbeta3 in the low affinity state. J Biol Chem (2004) 1.84
Structure of the integrin beta3 transmembrane segment in phospholipid bicelles and detergent micelles. Biochemistry (2008) 1.80
The conserved membrane-proximal region of an integrin cytoplasmic domain specifies ligand binding affinity. J Biol Chem (1995) 1.80
Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering. Proc Natl Acad Sci U S A (2005) 1.73
Glanzmann thrombasthenia. Orphanet J Rare Dis (2006) 1.65
Platelet integrin alpha(IIb)beta(3): activation mechanisms. J Thromb Haemost (2007) 1.63
How protein transmembrane segments sense the lipid environment. Biochemistry (2007) 1.50
The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res (2007) 1.42
EGF induces coalescence of different lipid rafts. J Cell Sci (2008) 1.38
Regulation of integrin alphaIIbbeta3 activation by distinct regions of its cytoplasmic tails. Biochemistry (2006) 1.36
Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood (2006) 1.35
Lipid rafts, fluid/fluid phase separation, and their relevance to plasma membrane structure and function. Semin Cell Dev Biol (2007) 1.31
Truncation of the cytoplasmic domain of beta3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin alpha(IIb)beta3 complex. J Clin Invest (1997) 1.26
Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica (2009) 1.13
Disruption of the beta3 663-687 disulfide bridge confers constitutive activity to beta3 integrins. Blood (2003) 1.06
Glanzmann's thrombasthenia: updated. Platelets (2002) 1.03
Transmembrane helices of membrane proteins may flex to satisfy hydrophobic mismatch. Biochim Biophys Acta (2006) 1.01
Cooperative role of the membrane-proximal and -distal residues of the integrin beta3 cytoplasmic domain in regulation of talin-mediated alpha IIb beta3 activation. J Biol Chem (2008) 0.89
A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost (2005) 0.86
Linkage of four polymorphisms on the alphaIIb gene. Br J Haematol (1998) 0.79
Thrombin induces GPIb-IX-mediated fibrin binding to alphaIIbbeta3 in a reconstituted Chinese hamster ovary cell model. J Thromb Haemost (2006) 0.77
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica (2009) 1.65
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica (2008) 1.62
Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med (2011) 1.49
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) (2011) 1.46
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood (2010) 1.29
Characterization of progressive periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix metalloproteinase-13, periodontal pathogens and inflammatory cells. J Clin Periodontol (2008) 1.17
[Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev Esp Cardiol (2007) 1.13
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
[Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation]. Rev Esp Cardiol (2004) 1.08
Disruption of the beta3 663-687 disulfide bridge confers constitutive activity to beta3 integrins. Blood (2003) 1.06
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer (2004) 1.03
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol (2006) 1.03
Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfus Apher Sci (2007) 1.02
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol (2013) 1.02
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. Am J Pathol (2005) 0.98
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97
Identification of cellular proteins modified in response to African swine fever virus infection by proteomics. Proteomics (2004) 0.95
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke (2006) 0.95
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J (2007) 0.95
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter. BMC Mol Biol (2006) 0.94
Thrombosis as a conformational disease. Haematologica (2005) 0.93
Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica (2005) 0.93
Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica (2011) 0.93
Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer (2013) 0.93
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood (2007) 0.92
Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood (2012) 0.92
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res (2008) 0.92
Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol (2007) 0.92
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Lab Invest (2008) 0.92
Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica (2009) 0.91
Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica (2010) 0.90
Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. Am Heart J (2004) 0.90
"Open rather than closed" malonate methano-fullerene derivatives. The formation of methanofulleroid adducts of Y3N@C80. J Am Chem Soc (2007) 0.90
Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int J Cardiol (2010) 0.90
Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol (2007) 0.89
Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Radiat Prot Dosimetry (2007) 0.89
Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation (2004) 0.88
Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J (2010) 0.88
Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. Breast Cancer Res Treat (2003) 0.88
Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol (2014) 0.87
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) (2012) 0.87
Deregulated expression of the PCPH proto-oncogene in human breast cancers. Int J Oncol (2004) 0.87
Treatment of the open abdomen with topical negative pressure therapy: a retrospective study of 46 cases. Int Wound J (2011) 0.87
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost (2014) 0.86
Involvement of ERK1/2, p38 and PI3K in megakaryocytic differentiation of K562 cells. Eur J Haematol (2010) 0.86
The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica (2007) 0.86
Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab (2009) 0.86
Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res (2012) 0.86
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab (2014) 0.85
SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. J Clin Invest (2015) 0.85
Safety evaluation and nutritional composition of a Fraxinus excelsior seed extract, FraxiPure™. Food Chem Toxicol (2012) 0.85
Type I Glanzmann thrombasthenia caused by an apparently silent beta3 mutation that results in aberrant splicing and reduced beta3 mRNA. Thromb Haemost (2005) 0.85
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica (2010) 0.85
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol (2005) 0.85
[Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia]. Gac Sanit (2011) 0.85
Identification of novel non-pathogenic mutation in SH3 domain of Btk in an XLA patient. Mol Immunol (2007) 0.85
Tuberculous meningitis: does lowering the treatment threshold result in many more treated patients? Trop Med Int Health (2008) 0.84
Regulatory regions of SERPINC1 gene: identification of the first mutation associated with antithrombin deficiency. Thromb Haemost (2012) 0.84
Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. Eur J Haematol (2013) 0.84
Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thromb Haemost (2010) 0.84
Home treatment of uncomplicated acute diverticulitis. Int Surg (2012) 0.84
Tuberculous meningitis: do modern diagnostic tools offer better prognosis prediction? Indian J Tuberc (2013) 0.83
[Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?]. Med Clin (Barc) (2011) 0.83
Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: identification of the second HPS7 mutation in a patient presenting late in life. Thromb Haemost (2013) 0.83
Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol (2004) 0.83
Potential role of miRNAs in developmental haemostasis. PLoS One (2011) 0.83
Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke (2014) 0.82
Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. J Lab Clin Med (2003) 0.82
Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem (2009) 0.82